Get the Stockscreener App
14.61
12.15%
-2.02
Instil Bio Inc stock is traded at $14.61, with a volume of 140.31K.
It is down -12.15% in the last 24 hours and down -16.51% over the past month.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
See More
Previous Close:
$16.63
Open:
$15.02
24h Volume:
140.31K
Relative Volume:
1.58
Market Cap:
$95.34M
Revenue:
-
Net Income/Loss:
$-74.14M
P/E Ratio:
-1.2827
EPS:
-11.39
Net Cash Flow:
$-65.70M
1W Performance:
-19.19%
1M Performance:
-16.51%
6M Performance:
-69.86%
1Y Performance:
+34.65%
1-Day Range:
$14.34
$16.32
1-Week Range:
$14.34
$18.92
52-Week Range:
$9.62
$92.00
Instil Bio Inc Stock (TIL) Company Profile
Name
Instil Bio Inc
Sector
Industry
Phone
(972) 499-3350
Address
3963 MAPLE AVENUE, DALLAS
Compare TIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TIL
Instil Bio Inc
|
14.61 | 95.34M | 0 | -74.14M | -65.70M | -11.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Instil Bio Inc Stock (TIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-25 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Perform |
| Apr-12-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-01-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-01-22 | Downgrade | Truist | Buy → Hold |
| Aug-13-21 | Initiated | Robert W. Baird | Outperform |
| Apr-13-21 | Initiated | Cowen | Outperform |
| Apr-13-21 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-21 | Initiated | Truist | Buy |
View All
Instil Bio Inc Stock (TIL) Latest News
Where are the Opportunities in (TIL) - news.stocktradersdaily.com
Tumor-infiltrating Lymphocyte (TIL) Therapies Global Market Report 2025: 75+ Therapies are Under Development and 100+ Clinical Trials are Underway Globally - GlobeNewswire Inc.
SEC Form 424B5 filed by Instil Bio Inc. - Quantisnow
(TIL) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Instil Bio, Inc. SEC 10-K Report - TradingView
Instil Bio Reports 2024 Financial Results and Outlook - TipRanks
Instil Bio reports Q4 adjusted EPS ($1.08) vs. ($1.26) last year - TipRanks
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
When (TIL) Moves Investors should Listen - Stock Traders Daily
Institutions along with private equity firms who hold considerable shares inInstil Bio, Inc. (NASDAQ:TIL) come under pressure; lose 12% of holdings value - Simply Wall St
Instil Bio: Time To Hop On The Summit Wave? (NASDAQ:TIL) - Seeking Alpha
(TIL) Technical Data - Stock Traders Daily
Private equity firms who hold 38% of Instil Bio, Inc. (NASDAQ:TIL) gained 34%, institutions profited as well - Yahoo Finance
(TIL) Investment Analysis and Advice - Stock Traders Daily
(TIL) Investment Report - Stock Traders Daily
What Makes Instil Bio (TIL) a New Buy Stock - MSN
Instil Bio Announces Clinical Progress in China for - GlobeNewswire
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody - Marketscreener.com
Instil Bio Advances Lung Cancer Treatment: First Patient Dosed in Phase 1b/2 Trial of Novel PD-L1xVEGF Therapy - StockTitan
Instil Bio Stock Soars After Jefferies Upgrade On 'Early Mover' Cancer Drug Candidate: Retail Jubilant - MSN
Jefferies Upgrades Instil Bio (TIL) - MSN
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside - Benzinga
These DFW stocks soared in 2024 - WFAA
How To Trade (TIL) - Stock Traders Daily
Instil Bio Secures Loan to Refinance Facility - MSN
Long Term Trading Analysis for (TIL) - Stock Traders Daily
Trend Tracker for (TIL) - Stock Traders Daily
Instil Bio’s Strategic Shift To SYN-2510: A Speculative ‘Buy’ Opportunity (NASDAQ:TIL) - Seeking Alpha
(TIL) Trading Report - Stock Traders Daily
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy - Yahoo Finance
Biontech acquiring PM-8002 through $950M Biotheus buyout - BioWorld Online
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Instil Bio Secures Global Rights to PD-L1xVEGF Drug, Reports $122.9M Cash Position | TIL Stock News - StockTitan
BioNTech Drops $800m To Acquire Bispecific Specialist Biotheus - insights.citeline.com
2 Stocks Up Over 700% in 2024 That Could Soar Even Further - AOL
JMP Securities initiates Instil Bio shares at Market Perform on public offering - Investing.com Australia
Instil Bio, Inc.'s (NASDAQ:TIL) stock price dropped 18% last week; private equity firms would not be happy - Simply Wall St
Summit Stock Skyrockets Nearly 700% YTD: Time to Sell or Hold? - Nasdaq
Analysis of Curative Ventures V LLC's Strategic Reduction in Instil Bio Inc - GuruFocus.com
(TIL) Long Term Investment Analysis - Stock Traders Daily
Baird maintains price target on Instil Bio stock, stays upbeat - Investing.com
5 Top NASDAQ Biotech Stocks of 2024 - Nasdaq
FDA Oncology Approvals Accelerate as Global Cancer Rates Set to Climb 77% - Baystreet.ca
Instil Bio Stock Skyrockets 641% in One Week: Here's Why - MSN
BOXER CAPITAL, LLC Acquires New Stake in Instil Bio Inc - GuruFocus.com
Baird sees Instil Bio stock upside on promising SYN-2510 clinical data - Investing.com UK
This is why everyone is talking about Summit TherapeuticsTHE BHARAT EXPRESS NEWS - The Bharat Express News
Instil Bio Inc Stock (TIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):